Translate Bio, Inc.

( )
TBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.00%64.320.0%$995.51m
NVAXNovavax, Inc. -2.13%94.25102.0%$760.16m
AMGNAmgen, Inc. 0.00%251.661.3%$718.41m
REGNRegeneron Pharmaceuticals, Inc. -0.23%639.162.5%$681.39m
GILDGilead Sciences, Inc. 2.58%76.641.0%$627.04m
BIIBBiogen, Inc. -0.25%278.001.6%$606.04m
VRTXVertex Pharmaceuticals, Inc. 0.00%295.401.9%$486.49m
ILMNIllumina, Inc. 1.11%376.753.5%$309.76m
VXRTVaxart, Inc. -1.22%8.090.0%$287.88m
ALXNAlexion Pharmaceuticals, Inc. 0.36%108.862.0%$218.89m
BMRNBioMarin Pharmaceutical, Inc. -0.40%126.304.3%$210.55m
SGENSeattle Genetics, Inc. -2.61%176.446.1%$200.28m
SRNESorrento Therapeutics, Inc. 1.16%7.841.8%$183.02m
IMMUImmunomedics, Inc. 0.00%42.3011.0%$182.18m
ALNYAlnylam Pharmaceuticals, Inc. -0.87%159.038.5%$162.24m

Company Profile

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.